Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi will pay French biotech Innate Pharma 25 million euros upfront for rights to a B7-H3-directed natural killer cell engager and options on two more…
Sanofi has signed a second NK cell engager licensing deal with Innate Pharma, this time for a B7-H3-targeted asset along with options on up to two additional…
FY2025 update: IPH62 (B7-H3) ANKET remains under preclinical development; Sanofi to lead development, manufacturing and commercialization upon candidate…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Announced Dec 19, 2022 and effective Jan 25, 2023 after Hart-Scott-Rodino clearance, Sanofi licensed Innate Pharma's B7-H3-targeted NK cell engager program (IPH62) from the ANKET platform, with options on up to two additional ANKET targets. Innate received EUR 25M (~$27M) upfront against up to EUR 1.35B (~$1.42B) in development, regulatory and commercial milestones plus royalties. The lead B7-H3 asset (IPH62) remains partnered and in preclinical development, with Sanofi to assume all development, manufacturing and commercialization upon candidate selection. The option/expansion component has since eroded: Sanofi exercised an option in Dec 2023 to license a second solid-tumor NKCE (IPH67) but terminated that license (notice Oct 9, 2024; effective Jan 7, 2025), returning IPH67 rights to Innate. As of Innate's FY2024 report Sanofi retained one further ANKET option. The deal thesis holds for the lead B7-H3 asset, but the multi-target platform-expansion upside that underpinned the headline milestone ceiling is materially reduced.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Innate Pharma SA (this deal) | 2022 | $1.4B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Oncology deals